Get the Stockscreener App
55.21
5.58%
2.92
After Hours:
55.21
Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News
Rhythm Pharmaceuticals receives orphan drug status in Japan By Investing.com - Investing.com Australia
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted To Setmelanotide For Treatment Of Hypothalamic Obesity In Japan - Marketscreener.com
Rhythm Pharmaceuticals receives orphan drug status in Japan - Investing.com
Rhythm Pharmaceuticals Receives Orphan-Drug Designation in Japan for Obesity Treatment - MarketWatch
Rhythm Pharmaceuticals Announces Orphan Drug Designation - GlobeNewswire
Breakthrough for Rare Obesity: Rhythm's Drug Wins Special Status in Japan - StockTitan
Charles Schwab Investment Management Inc. Has $24.65 Million Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Rhythm Pharmaceuticals (NASDAQ:RYTM) Given New $66.00 Price Target at Needham & Company LLC - Defense World
Rhythm Pharmaceuticals EVP sells shares worth $3.86 million - Investing.com
Needham raises Rhythm Pharma stock target to $66, maintains buy By Investing.com - Investing.com UK
Rhythm Pharmaceuticals and Raymond A. Wood Foundation Launch Research Collaboration on Fatigue in Craniopharyngioma Patients - Nasdaq
Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration - GlobeNewswire
Major Breakthrough: Rhythm Pharma's New Research Tackles Devastating Fatigue in Brain Tumor Patients - StockTitan
Bank of New York Mellon Corp Sells 680 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Insider Sell Alert: EVP, Head of North America Jennifer Lee Sells Shares of Rhythm Pharmaceuticals Inc (RYTM) - GuruFocus.com
How To Trade (RYTM) - Stock Traders Daily
SBI Securities Co. Ltd. Invests $37,000 in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Stifel maintains Buy on Rhythm Pharmaceuticals, $78 target By Investing.com - Investing.com Canada
Stifel maintains Buy on Rhythm Pharmaceuticals, $78 target - Investing.com India
Reviewing Wave Life Sciences (NASDAQ:WVE) & Rhythm Pharmaceuticals (NASDAQ:RYTM) - Defense World
Rhythm Pharmaceuticals (NASDAQ:RYTM) Earns Overweight Rating from Morgan Stanley - Defense World
Assessing Rhythm Pharmaceuticals: Insights From 10 Financial Analysts - Benzinga
Promising Outlook for Rhythm Pharmaceuticals: Buy Rating Backed by Positive Phase 3 Study Expectations and Market Potential - TipRanks
Stifel Nicolaus Begins Coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) - Defense World
Analysts Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) PT at $68.27 - Defense World
HC Wainwright Brokers Raise Earnings Estimates for RYTM - Defense World
Citizens JMP maintains Rhythm Pharma Outperform, $81 target By Investing.com - Investing.com South Africa
Citizens JMP maintains Rhythm Pharma Outperform, $81 target - Investing.com India
Principal Financial Group Inc. Purchases 4,298 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Brokers Issue Forecasts for RYTM FY2026 Earnings - Defense World
Promising Market Potential for Rhythm Pharmaceuticals’ Setmelanotide in Treating Hypothalamic Obesity - TipRanks
Stifel raises Rhythm Pharmaceuticals stock to Buy with $78 target By Investing.com - Investing.com Canada
US High Growth Tech Stocks to Watch in March 2025 - Yahoo Finance
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates - MSN
Y Intercept Hong Kong Ltd Invests $328,000 in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
HC Wainwright Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price - Defense World
Rhythm Pharmaceuticals Faces Financial Risks Due to Convertible Preferred Stock Prioritization - MSN
Rhythm Pharmaceuticals stock target raised to $70 at H.C. Wainwright - Investing.com India
Learn to Evaluate (RYTM) using the Charts - Stock Traders Daily
Decoding Rhythm Pharmaceuticals Inc (RYTM): A Strategic SWOT Ins - GuruFocus.com
Needham & Company LLC Reaffirms “Buy” Rating for Rhythm Pharmaceuticals (NASDAQ:RYTM) - Defense World
Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - Defense World
Rhythm Pharmaceuticals (NASDAQ:RYTM) Posts Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $81.00 - MarketBeat
Rhythm Pharmaceuticals sets annual meeting for June 24 By Investing.com - Investing.com South Africa
Rhythm Pharmaceuticals sets annual meeting for June 24 - Investing.com
Rhythm Pharmaceuticals (NASDAQ:RYTM) Earns Buy Rating from Needham & Company LLC - MarketBeat
RHYTHM PHARMACEUTICALS, INC. SEC 10-K Report - TradingView
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Purchased by Rhumbline Advisers - Defense World
Rhythm Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - TipRanks
Citizens JMP raises Rhythm Pharma stock target to $81 By Investing.com - Investing.com Canada
State of New Jersey Common Pension Fund D Makes New Investment in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2024 Earnings Call Transcript - Insider Monkey
Canaccord lifts Rhythm Pharma stock target to $81, keeps Buy rating By Investing.com - Investing.com South Africa
Rhythm Pharmaceuticals: Strong Buy Rating Backed by IMCIVREE’s Growth and Promising Pipeline Developments - TipRanks
Canaccord lifts Rhythm Pharma stock target to $81, keeps Buy rating - Investing.com UK
We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Can Afford To Drive Business Growth - Yahoo Finance
Rhythm Pharmaceuticals Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line - Yahoo Finance
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):